PUBLIC HEALTH SERVICE FIRST AMENDMENT TO EXCLUSIVE LICENSE AGREEMENT (L-068-02/0)Exclusive License Agreement • August 14th, 2002 • Paligent Inc • Biological products, (no disgnostic substances)
This Amendment of the Exclusive Patent License L-068-02/0 (“Agreement”), L-068-02/1 (“Amendment”), is made between the National Institutes of Health (“NIH”), the Centers for Disease Control and Prevention (“CDC”), or the Food and Drug Administration (“FDA”), hereinafter singly or collectively referred to as (“PHS”), agencies of the United States Public Health Service within the Department of Health and Human Services (“DHHS”) through the Office of Technology Transfer, NIH, having an address at 6011 Executive Boulevard, Suite 325, Rockville, Maryland 20852-3804, U.S.A., Procept, Inc., having offices at the address indicated on the Signature Page, hereinafter referred to as “Licensee”.
APPENDIX –J COMPREHENSIVE RELEASE AGREEMENTComprehensive Release Agreement • August 14th, 2002 • Paligent Inc • Biological products, (no disgnostic substances) • District of Columbia
This agreement (this “Agreement”) is entered into by and among Procept, Inc. (formerly Pacific Pharmaceuticals, Inc.) (“Procept”), AOI Pharmaceuticals, Inc. (a subsidiary of Access Oncology, Inc.) (“AOIP”), and the United States Public Health Services (“PHS”), and both the Penn State Research Foundation (“Foundation”), the University of Chicago (“UC”) (Procept, AOIP and PHS, Foundation and UC collectively, the “Parties”).
